Cardiogenic shock (CS) is a common cause of mortality, and management remains challenging despite advances in therapeutic options. CS is caused by severe impairment of myocardial performance that results in diminished cardiac output, endâ€organ hypoperfusion, and hypoxia. Clinically this presents as hypotension refractory to volume resuscitation with features of endâ€organ hypoperfusion requiring pharmacological or mechanical intervention. Acute myocardial infarction (MI) accounts for 81% of patient in CS
Cardiogenic shock is a clinical entity characterized by a low cardiac output state of circulatory failure that results in end-organ hypoperfusion and tissue hypoxia. The most common cause of cardiogenic shock is acute myocardial infarction, though other disorders leading to impairment of the myocardium, valves, conduction system, or pericardium also can result in cardiogenic shock. Despite advances in reperfusion therapy and mechanical circulatory support treatments, morbidity, and mortality among patients with cardiogenic shock remain high